Equity Field Notes from temporal sources

[DanWebzster]

CTIC 's Pacritinib program endures as a prospective treatment against Myelofibrosis (MF).

Allogeneic transplantation is the first line treatment against excessive scar tissue in the bone marrow. INCY and CELG have competing second line treatments; but, their drugs are no longer indicated in patients with a platelet count < 50,000/ml.

This category is up to 35% of all MF patients. The FDA has granted CTIC accelerated review if Pacritinib tests well in this subset.

Although Pacritinib's previous Ph3 results prompted a clinical hold due to patient deaths, FDA has sanctioned a redesigned Ph2 study. Results will be read out in early 2022.

CTIC had cash of $70.1M mid-2020 and a burn rate of ~40M/year.

CTIC also has a me-too Covid program.

I might consider buying CTIC on a sharp decline during 2021 for a run-up into Pacritinib Ph2 data.